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to the misdiagnosis aspect of monocytic leukemia or histio-
cytic neoplasm. Regarding immunohistochemical anoma-
lies, mast cells in aggressive and leukemic SM have been 
found to express CD30 (Ki1-antigen). Thus, anaplastic large 
cell lymphoma or Hodgkin’s disease may first be considered 
rather than SM. There is increasing evidence that most pa-
tients with long-standing adult-type urticaria pigmentosa-
like skin lesions have in fact indolent SM. Therefore, such skin 
lesions are an important clue to the correct diagnosis in 
these patients. However, in aggressive or leukemic SM skin 
lesions are usually absent and then the correct diagnosis re-
lies on an appropriate investigation of bone marrow biopsy 
specimens using both SM-related immunohistochemical 
markers (tryptase, KIT, CD25, CD30) but also markers exclud-
ing potential differential diagnoses. Investigation for pres-
ence of the activating  KIT point mutation D816V is very help-
ful to establish a correct diagnosis of SM in all the difficult 
cases exhibiting a low degree of bone marrow infiltration or 
puzzling morphological findings. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Mastocytosis is a hemopoietic disorder of bone mar-
row origin comprising an extremely heterogeneous array 
of subentities with greatly varying clinical and pathomor-
phological features  [1] . The complexity of this unusual 
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 Abstract 
 Diagnosis of systemic mastocytosis (SM) is mainly based on 
the morphological demonstration of compact mast cell infil-
trates in various tissue sites. In almost all patients such infil-
trates are detected in the bone marrow. Reliable immunohis-
tochemical markers for the diagnosis and grading of SM have 
been established, but various differential diagnoses includ-
ing myeloproliferative neoplasms, basophilic and eosino-
philic leukemias may be very difficult to delineate. Even 
more challenging is the recognition of hematological neo-
plasms with signs of mast cell differentiation but not fulfill-
ing diagnostic criteria for SM, especially the rare myelomas-
tocytic leukemia. It is also important to separate the reactive 
state of mast cell hyperplasia from indolent variants of SM, 
especially those with a very low degree of bone marrow in-
filtration and absence of compact mast cell infiltrates. When 
the lymphocytic component of the SM infiltrate is very 
prominent, SM may be confused with an indolent lympho-
ma, especially lymphoplasmacytic lymphoma which almost 
always shows a marked reactive increase in mast cells. In ag-
gressive and leukemic variants of SM, mast cells may be very 
atypical and devoid of metachromatic granules. This hypo-
granulation can be regarded as cellular atypia and may lead 
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disorder can best be shown by the fact that a hemopoietic 
stem cell-derived disorder in most patients primarily 
presents as a dermatological disease. The common de-
nominator of mastocytosis is the demonstration of multi-
focal compact tissue mast cell infiltrates  [2] . The presence 
of such compact mast cell infiltrates outside the skin is the 
key finding for systemic mastocytosis (SM). Compact 
mast cell infiltrates are considered as a major diagnostic 
criterion and represents a crucial indicator for the pathol-
ogist to be able to correctly assess or exclude mastocytosis 
morphologically. The multifaceted features of mastocyto-
sis explain the broad range of differential diagnoses, in-
cluding reactive and neoplastic states. Moreover, the list 
of differential diagnoses varies according to the diagnos-
tic approach to the disease. While patients with long-
standing adult-type urticaria pigmentosa (the most com-
mon form of cutaneous mastocytosis) are staged for the 
presence of indolent systemic mastocytosis (ISM) by in-
vestigation of bone marrow trephine biopsy specimens, 
isolated bone marrow mastocytosis as a special subvariant 
of ISM without skin involvement is an incidental finding 
in a small subgroup of patients with suspected hemato-
logical disorders, unexplained osteoporosis, or severe 
anaphylaxis after bee or wasp stings.
 In the following, morphological and molecular key 
features for the diagnosis of mastocytosis are presented 
together with clues for proper subclassification but also 
for delineation of mast cell hyperplasia, hematological 
disorders with signs of mast cell differentiation not ful-
filling diagnostic criteria of mastocytosis and the large 
panel of possible differential diagnoses within the spec-
trum of hematological neoplasms.
 Material and Methods 
 The present study is based on archival material gathered in a 
Center of Reference for Hematopathology of Mastocytosis within 
the European Competence Network of Mastocytosis (ECNM) lo-
cated at the Institute of Pathology in Ansbach, Germany. The reg-
istry consists of nearly 700 cases of well-documented mastocyto-
sis including immunohistochemical and molecular pathological 
findings. All subtypes of mastocytosis were recorded. All cases 
were analyzed immunohistologically with antibodies against the 
mast cell-related antigens tryptase and CD117 (KIT) but also 
against CD25 and CD30 to assess an aberrant phenotype of mast 
cells that is only present in neoplastic states of mastocytosis. As-
sociation of SM with a hematological non-mast cell clonal dis-
order (SM-AHNMD) makes it necessary to apply a larger panel
of antibodies to be able to subclassify the ‘AHNMD’ according
to WHO criteria. When available, smears of blood and bone mar-
row were also investigated with special attention to the number 
and cytomorphological aspects of mast cells.
 Diagnostic Criteria for Mastocytosis  [3] 
 (1) Main criterion.
 Multifocal compact tissue infiltrate of mast cells.
 (2) Minor criteria.
 (2.1)  Prominent spindling of mast cells ( 1 25%).
 (2.2) Aberrant immunophenotype of mast cells with 
expression of CD25 (and/or CD2).
 (2.3) Activation point mutations at codon 816 of KIT 
(usually D816V).
 (2.4) Chronically elevated serum tryptase ( 1 20 ng/ml).
 Diagnosis of mastocytosis can be established if the 
major and at least 1 minor criterion or at least 3 minor 
criteria are fulfilled. 
 Note that the diagnosis of mastocytosis is only possi-
ble when appropriate investigations are performed by the 
pathologist. Morphological criteria (1, 2.1 and 2.2) alone 
are sufficient to enable a diagnosis of mastocytosis to be 
confirmed by the pathologist. In cases where the major 
criterion is missing, however, at least one additional mo-
lecular and/or serological finding has to be considered. 
Altogether, in about 20% of cases compact mast cell infil-
trates cannot be detected and diagnosis of mastocytosis 
is based on 3 or 4 minor criteria.
 Immunohistochemical Key Features 
 Immunohistochemical diagnosis of SM in the bone 
marrow (but also in other tissue sites) requires three 
 antibodies directed against the following antigens: trypt-
ase, CD117 (KIT) and CD25  [4] . In most patients with 
SM-AHNMD, diagnosis of the ‘AHNMD’ can be achieved 
only by application of a broader panel of antibodies pend-
ing on the suspected subtype of the associated neoplasm. 
Cases missing any compact mast cell infiltrates cannot be 
diagnosed without immunohistochemistry. It is essential 
to be aware that mast cells in reactive and neoplastic 
states and all stages of maturation coexpress tryptase  and 
CD117. Cells expressing only tryptase or CD117, respec-
tively, are  not  mast cells. Round tryptase-positive CD117-
negative cells can be basophilic granulocytes or myelo-
blasts. An increase in such cells is seen in neoplastic states 
like basophilic leukemia, chronic myeloid leukemia or 
myelomastocytic leukemia. Rarely, compact infiltrates 
consisting exclusively of round tryptase-expressing cells 
are detected, a finding which has been termed TROCI-
bm and which is seen only in neoplastic states  [5] . TRO-
CI-bm deserves further immunohistochemical clarifica-
tion using antibodies against CD117, CD25, and CD34. 
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Focal TROCI-bm occurs in common-type SM, in well-
differentiated SM (note: mast cells are CD25-negative 
here), in basophilic and chronic myeloid leukemias while 
diffuse TROCI-bm is encountered in aggressive SM, mast 
cell leukemia, tryptase-positive acute myeloid leukemia 
and myelomastocytic leukemia. CD117-positive tryptase-
negative cells can be progenitor/blast cells or immature 
erythroblasts but are also seen in the setting of some sol-
id neoplasm that hardly infiltrate the bone marrow (gas-
trointestinal stroma tumor/GIST, seminoma, malignant 
melanoma, etc.). However, virtually all spindle-shaped 
tryptase-expressing cells are in fact mast cells. Expres-
sion of CD25 by mast cells defines a phenotypic aber-
rancy that is almost exclusively seen in mastocytosis  [6] . 
One of the rare exceptions to the rule is myeloprolifera-
tive neoplasms with eosinophilia (MPNEo) which may 
contain large numbers of spindle-shaped CD25-positive 
mast cells usually without fulfilling diagnostic criteria 
for SM  [7] . Recent findings yielded a usually strong ex-
pression of CD30 on neoplastic mast cells in the setting 
of aggressive or leukemic SM, whereas CD30 expression 
was low or even missing in most cases of indolent SM 
[own unpubl. obs.].
 In the following, morphological key diagnoses are de-
fined and the differential diagnostic aspects of the dis-
ease are highlighted ( table 1 ).
 Mast Cell Hyperplasia 
 By definition, mast cell hyperplasia represents a re-
active increase in mast cells with very characteristic 
 morphological features. Mast cells are loosely scattered 
throughout the tissues without tendency to form com-
pact infiltrates ( fig. 1 ). Usually, mast cells are round and 
contain abundant metachromatic granules. However, 
collagen fibrotic tissue may also contain increased num-
bers of mast cells which here show a spindle-shaped ap-
pearance and resemble fibrocytes/fibroblasts in conven-
tional HE staining. Such fibrotic foci may easily be mis-
interpreted as mastocytosis. Since mast cells here do not 
aggregate in dense clusters and do not express CD25, 
this is not mastocytosis but rather could be preliminar-
ily, termed ‘fibromastocytic lesion’. Compact groups of 
mast cells have very rarely been seen in patients treated 
with hematopoietic growth factors like SCF. Three sub-
variants of mastocytosis have to be separated from mast 
cell hyperplasia:
 (1) Indolent SM, especially regarding the usually low de-
gree of bone marrow infiltration. 
 (2) Isolated SM of the bone marrow which also shows a 
low degree of infiltration. 
Table 1.  SM: main differential diagnoses
Diagnosis Differential diagnosis
Mast cell hyperplasia Indolent SM
Occult mastocytosis
Well-differentiated SM
Indolent SM Mast cell hyperplasia
Occult mastocytosis
Cutaneous mastocytosis
Isolated mastocytosis of BM
Smoldering SM
Non-Hodgkin’s lymphoma
Hairy cell leukemia
Histiocytic neoplasm
Granulomatous disease
Smoldering SM Myeloproliferative neoplasm
Eosinophilic leukemia
Malignant lymphoma
CMML
SM-AHNMD
Aggressive SM Smoldering SM
Aleukemic MCL
SM-AHNMD
CD30+ malignant lymphoma
MCL Aggressive SM
Aleukemic MCL
Basophilic leukemias
Myelomastocytic leukemia
SM-AHNMD
Tryptase+ AML
CD30+ malignant lymphoma
SM-AHNMD Aggressive SM
Myelomastocytic leukemia
‘CD30+ mastocytosis’ Hodgkin’s lymphoma
Anaplastic LCL
Seminoma
‘CD68+ mastocytosis’* Histiocytosis
Monocytic leukemia
‘CD25+ mastocytosis’* Hairy cell leukemia
S M = Systemic mastocytosis; BM = bone marrow; MCL = mast 
cell leukemia; AHNMD = associated hematologic non-mast cell 
disorder; LCL = large cell lymphoma; CMML = chronic myelo-
monocytic leukemia.
* In most patients with SM, MC are CD68+ and CD25+.
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 (3) Well-differentiated SM  [8] , considering the cytomor-
phology of cells that are exclusively round and that do 
not express CD25 ( fig. 2 ). 
 In contrast to mast cell hyperplasia where round mast 
cells dominate the picture, indolent SM and isolated bone 
marrow SM usually show increased numbers of spindle-
shaped mast cells exhibiting an atypical immunopheno-
type expressing CD25 ( fig. 3,  4 ). In most cases at least a 
few small compact mast cell infiltrates can be detected 
when appropropriate immunostainings like tryptase and 
anti-CD117 are applied  [9] . The demonstration of the ac-
tivating point mutation KITD816V in the overwhelming 
majority of cases clearly underlines such histological 
findings to be interpreted as clonal expansion of intra-
medullary mast cells in the setting of mastocytosis  [10] .
 Indolent Systemic Mastocytosis  
 Indolent systemic mastocytosis (ISM) usually shows a 
multifocal but low degree of bone marrow infiltration 
(less than 5% of section area) and is the most common 
diagnosis for adult patients with long-standing urticaria 
pigmentosa (cutaneous mastocytosis). ISM has to be sep-
arated from mast cell hyperplasia, indolent lymphoma 
and some subtypes of SM that usually also show a minor 
degree of bone marrow infiltration.
 (1) Isolated bone marrow mastocytosis is incidentally 
detected in a subgroup of patients with anaphylactic 
reactions after hymenoptera stings. Since these  pa-
tients usually have no skin lesions of urticaria pig-
mentosa, it is crucial for the pathologists to assess or 
exclude SM by applying immunohistochemistry in 
all cases. If spindle-shaped loosely scattered CD25-
positive mast cells are detected, even in low numbers, 
a molecular pathological analysis has to performed. 
Many of these patients then are found to have SM 
based on three minor diagnostic criteria (e.g. aber-
rant immunophenotype, KITD816V and elevated se-
rum tryptase) since compact mast cell infiltrates are 
often missing. 
 (2) Cutaneous mastocytosis should be diagnosed in the 
adult only after histological investigation of an ade-
quate bone marrow trephine biopsy specimen. Our 
own unpublished observations show that most but not 
all patients with long-standing urticaria pigmentosa-
like skin lesions do in fact have ISM. In contrast, al-
most all children with cutaneous mastocytosis do not 
have systemic disease, although it should be stated
that their bone marrow is usually not evaluated histo-
logically. The notion of a pure juvenile-type of cutane-
ous mastocytosis is underlined by the fact that most 
 Fig. 1. Mast cell hyperplasia. Extremely hypercellular bone mar-
row with packed infiltration by a lymphocytic lymphoma. Note 
the increase in loosely scattered round strongly metachromatic 
mast cells without tendency to group or to form compact infil-
trates. Mast cell hyperplasia is a very common finding in this type 
of malignant lymphoma. Giemsa. 
 Fig. 2. Well-differentiated systemic mastocytosis. Small compact 
infitrate exclusively consisting of round mast cells that strongly 
react with chloroacetate esterase. Naphthol AS-D chloroacetate 
esterase. 
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patients show spontaneous regression of skin efflores-
cences at puberty  [11] . 
 (3) Well-differentiated SM is easily excluded by the ab-
sence of aberrant CD25 expression. It is important to 
be aware that rare cases of ‘common’ type ISM with 
exclusive round cell appearance do exist ( fig. 5 ). 
 (4) Smoldering and aggressive SM may be difficult to ex-
clude in some exceptional cases of ISM with extensive 
infiltration of the bone marrow (up to 70% of section 
area). The presence of B-findings (organomegaly) indi-
cates smoldering SM which often shows KITD816V 
mutation in non-mast cell-lineage cells and cytological 
atypia of blood cell precursors. The full picture of a my-
elodysplastic syndrome (MDS), however, is not present 
and SM-AHNMD should not be diagnosed. The pres-
ence of C-findings (indicating organ insufficiency due 
to mast cell infiltration) is the key finding for the diag-
nosis of aggressive SM. 
 (5) Cases of ISM may show disseminated follicle-like lym-
phocytic aggregates adjacent to or intermingled with 
the neoplastic mast cells leading to the primary aspect 
of a low-grade malignant non-Hodgkin’s lymphoma at 
first glance. Lymphocytic lymphomas (chronic lym-
phocytic leukemia/CLL and lymphoplasmacytic lym-
phoma) here are easily misdiagnosed due to their high 
 Fig. 3. Indolent systemic mastocytosis. Loosely scattered spindle-
shaped mast cells with aberrant immunophenotype and expres-
sion of CD25 can easily be detected. This is a very typical finding 
in indolent systemic mastocytosis, but without presence of com-
pact infiltrates (not depicted) the presented morphological as-
pects alone do not fulfill criteria for diagnosis of systemic masto-
cytosis. Anti-CD25 (ABC method). 
 Fig. 4. Mast cell leukemia. Cytomorphology of a bone marrow 
smear showing a striking increase in mast cells with expression 
of CD25. Quantitative aspects fulfill criteria for diagnosis of mast 
cell leukemia. Anti-CD25 (ABC method). 
 Fig. 5. Indolent systemic mastocytosis. Large compact infiltrate 
exclusively consisting of round mast cells is shown. Since mast 
cells clearly express CD25, this is not a case of well-differentiated 
systemic mastocytosis. Anti-CD25 (ABC method). 
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content of mast cells. However, lymphocytes in ISM 
usually show no immunophenotypical anomalies. An 
extremely uncommon finding is an association of SM 
with CLL perfectly imitating the histological picture 
of indolent SM with mixed (mast cell/lymphocyte) in-
filtrates. Diagnosis of CLL here could be only con-
firmed by the presence of an atypical immunopheno-
type of lymphocytes coexpressing CD5, CD20 and 
CD23  [12] . 
 Aggressive Systemic Mastocytosis 
 Aggressive systemic mastocytosis (ASM) is morpho-
logically characterized by a marked degree of bone mar-
row infiltration ( 1 30%) which may be either multifocal 
or diffuse-compact  [13] . ASM has to be separated from 
other high-grade variants of SM and a few rare myeloid 
neoplasms.
 (1) The major differential diagnosis of ASM is SM- 
AHNMD since the ‘AHNMD’ may be almost ob-
scured by the massive mast cell infiltrate but is often 
easily detectable when blood and bone marrow smears 
are investigated. 
 (2) Mast cell leukemia may show very similar histological 
pictures as can be seen in ASM as well as a comparable 
degree of bone marrow infiltration. In typical cases of 
mast cell leukemia, the degree of reticulin fibrosis is 
markedly lower than in ASM. Moreover, there is a 
more diffuse (‘leukemia-like’) infiltration pattern in 
mast cell leukemia contrasting to the more multifocal 
involvement seen in ASM. It is of outstanding impor-
tance to analyze blood and bone marrow smears. In 
mast cell leukemia more than 20% of nucleated bone 
marrow cells have to be identified as mast cells (count-
ing of mast cells should not be performed in or around 
the crushed particles). Moreover, ASM may progress 
into most cell leukemia (secondary MCL). 
 (3) Separation of ASM from smoldering SM and ISM is 
not always possible on the basis of bone marrow histol-
ogy alone. 
 (4) It may be very difficult or even impossible to separate 
hematological neoplasms like monocytic leukemia, 
basophilic and eosinophilic leukemia, malignant his-
tiocytosis ( fig. 6, 7 ), hairy cell leukemia, myelomasto-
cytic leukemia and tryptase-positive acute myeloid 
leukemia from ASM unless immunohistochemical 
staining is applied. 
 (5) A major proportion of cases with high-grade SM 
(ASM, SM-AHNMD and mast cell leukemia) show 
strong expression of CD30 by a majority of neoplastic 
mast cells ( fig. 8–12 ). Unless antitryptase staining is 
performed, diagnoses of malignant lymphoma (Hodg-
kin’s sarcoma, anaplastic large cell lymphoma) or even 
malignant germ cell tumor may be considered. 
 Fig. 6, 7. Malignant histiocytosis. Diffuse infiltration of the bone 
marrow by histiocytic medium-sized cells with aplasia of normal 
blood cell precursors and fat cells. Note the marked osteosclerosis. 
Immunophenotypical analysis revealed expression of histiocyte-
related antigens like CD68 and CD163 by neoplastic cells (not de-
picted). Since all myeloid antigens including tryptase were com-
pletely negative, this case was regarded as an extremely rare ‘true’ 
malignant histiocytosis. HE. 
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8 9
1110
 Fig. 8–12. Mast cell leukemia. Mast cell leukemia with diffuse in-
filtration of the bone marrow is shown. Note the dilated sinus-like 
prominent vessels. Mast cells coexpress tryptase and CD117 (not 
depicted) but also CD30. Since some multinucleated CD30-pos-
itive giant cells are present, diagnosis of a malignant lyphoma was 
initially considered. Cellular bone marrow smears reveal an 
abundance of round hypogranulated, often vacuolated mast cells. 
HE (fig.  8, 9). Antitryptase/AA1 (ABC mehod) (fig.  10). Anti-
CD30 (fig. 11). Wright-Giemsa (fig. 12). 12
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 Mast Cell Leukemia  
 Mast cell leukemia (MCL) is a very rare hematological 
disease within the spectrum of mastocytosis due to its 
unique cytomorphological, immunophenotypical and 
molecular pathological features  [14] . It is likely that MCL 
belongs to the rarest forms of human leukemias. Mor-
phologically, typical cases of MCL show a diffuse-com-
pact bone marrow infiltration with marked reduction of 
fat cells and blood cell precursors. As previously stated, 
MCL is defined by an increase in mast cells in bone mar-
row smears exceeding 20% of all nucleated cells. Presence 
of circulating mast cells in the blood (at least 10% of leu-
kocytes) separates MCL from its (more common) aleuke-
mic subvariant. Cytomorphologically, two major sub-
types of MCL are distinguishable: the common round-
cell and the rare spindle-cell variant ( fig.  13–15 ). MCL 
must be separated from other high-grade variants of SM 
and some non-mast cell hematological neoplasms. 
 (1) Aggressive (but also smoldering and, rarely, indolent) 
SM are histologically indistinguishable from MCL be-
cause the bone marrow can be diffusely infiltrated in 
all these subvariants of SM. 
 (2) SM-AHNMD is very difficult to assess or exclude be-
cause the leukemic infiltration may almost obscure 
the ‘AHNMD’ which can only be recognized by me-
ticulous analysis of blood and bone marrow smears 
 [15] . Cases of MCL associated with myelodysplastic 
syndromes and chronic myelomonocytic leukemia do 
exist thus enabling diagnoses like MCL-MDS or MCL-
CMML to be established. 
 Fig. 13–15. Mast cell leukemia. Cytomorphological aspects of 
mast cell leukemia in bone marrow smears. Figures 13 and 14 
show the more common round cell type, while figure 15 reveals 
the rare spindle-shaped variant of mast cell leukemia. Mast cells 
in both subvariants are hypogranulated. Normal blood cell pre-
cursors are almost absent. Wright-Giemsa. 
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 Fig. 16–20. Chronic basophilic leukemia. Bone marrow histology 
has features of an uncommon myeloproliferative or myelodys-
plastic neoplasm. Immunohistochemical investigations reveal 
clusters of CD117-positive but tryptase-negative medium-sized 
blast cells. There is also an increase in small round tryptase-pos-
itive CD117-negative cells which can be identified as basophils by 
using an antibody against the basophil-specific antigen 2D7 (not 
commercially available). Blood smear shows an increase in circu-
lating basophils constituting more than 50% of all leukocytes. Cy-
togenetics did not reveal the bcr-abl fusion gene. HE (fig. 16). An-
ti-CD117 (ABC method) (fig. 17). Antitryptase/AA1 (fig. 18). An-
ti-2D7 (fig. 19). Wright-Giemsa. 
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 (3) The common round-cell variant of MCL must be sep-
arated from myelomastocytic and basophilic leuke-
mia. By definition, the extremely rare myelomastocyt-
ic leukemia shows features of mast cell differentiation 
but does not fulfill criteria of SM, especially the acti-
vating point mutation KITD816V is missing as well as 
compact mast cell infiltrates  [16] . 
 Tryptase-positive acute myeloid leukemia (T+AML) 
should be separated from myelomastocytic leukemia. 
T+AML is characterized by a significant increase in 
tryptase-expressing blast cells in an otherwise unre-
markable AML which usually exhibits immunopheno-
typical characteristics of subtype FABM1. Basophilic leu-
kemia may be difficult to separate from MCL because 
there is an abundance of round tryptase-expressing neo-
plastic cells in both neoplasms. While mast cells of MCL 
must show expression of CD117 (KIT), this antigen is 
missing on neoplastic basophils of basophilic leukemia 
( fig. 16–20 ). The spindle-shaped variant of MCL is very 
rare. Differential diagnosis includes a variety of here ex-
tremely uncommon tumors like gastrointestinal stromal 
tumor (GIST), malignant melanoma, spindle-shaped 
plasma cell myeloma  [17] and mesenchymal tumors with 
prominent fibroblastic differentiation.
 Myelomastocytic Leukemia  
 The most important differential diagnosis of MCL is 
myelomastocytic leukemia (MML). In MML, the chance 
to be cured by stem cell transplantation may be better 
compared to MCL and ASM. MML is an advanced my-
eloid neoplasm with an increase in blast cells (usually 
RAEB or overt AML) but also a marked increase in im-
mature MC and/or metachromatic blast cells (more than 
10% of nucleated cells in bone marrow smears). Mast cells 
in MML usually express CD117 and tryptase but lack CD2 
and CD25  [18] . The KIT mutant D816V is not detectable, 
but rarely other KIT mutations are found. MC are not 
spindle-shaped and never form compact focal infiltrates 
thus clearly contrasting to the common findings in SM. 
Immunohistochemical markers that should be applied in 
suspected MML are CD34, CD117, tryptase, and CD25.
 SM-AHNMD 
 The association of SM with a non-mast cell hemato-
logical neoplasm is termed SM-AHNMD. Following 
ISM, SM-AHNMD represents the second most frequent 
subvariant of SM  [19] . Almost all defined subtypes of my-
eloid neoplasms but also plasma cell myeloma and, very 
rarely, malignant lymphomas have been identified as 
‘AHNMD’  [20] . SM-AHNMD is often a very challenging 
diagnosis for the hematopathologist and the various dif-
ferential diagnoses depend on the degree of bone marrow 
infiltration.
 (1) So-called occult SM is the most important differential 
diagnosis in cases with prominent ‘AHNMD’ which 
may completely obscure minor mast cell infiltrates. In-
filtrates of SM may become visible in patients with SM-
AML only after cytoreductive therapy and remission 
of the ‘AHNMD’  [21] . Thus, patients show remission of 
an aggressive hematological neoplasm but now exhibit 
features of another less aggressive, clonal hematologi-
cal tumor. Routine use of antibodies against tryptase, 
CD117 and CD25 enables to reveal associated (‘occult’) 
SM in not less than 5% of the cases. Such cases show a 
mild increase in loosely scattered often spindle-shaped 
mast cells with aberrant immunophenotype and CD25 
expression but small compact infiltrates are hardly de-
tected even after meticulous search. 
 (2) Regarding a minority of SM-AHNMD cases with dif-
fuse-compact infiltration of the bone marrow, the ini-
tial diagnosis is aggressive SM or MCL. SM-AHNMD 
in such cases cannot be excluded unless cytomorpho-
logical evaluation of blood and bone marrow smears 
is performed. 
 (3) Many SM patients with marked persistent increase
in circulating eosinophils clinically present with 
chronic eosinophilic leukemia (CEL, NOS) or myelo-
proliferative neoplasms with eosinophilia (MPNEo). 
Most cases of MPNEo exhibit a significant increase of 
spindle-shaped mast cells with aberrant immunophe-
notype and expression of CD25 but do not form com-
pact (diagnostic) infiltrates ( fig. 21–24 ). Evaluation of 
bone marrow histology may reveal SM-AHNMD (SM-
CEL/MPNEo) or ‘pure’ SM with eosinophilia (‘SM-
EO’). It is important to be aware that SM-MPNEo does 
exist and morphological criteria of SM with multifocal 
compact mast cell infiltrates are clearly fulfilled  [22] . 
However, synchronous occurrence of a cytogenetic 
anomaly in the PDGR (alpha or beta) which is crucial 
for the diagnosis of MPNEo with an activating point 
mutation KITD816V has not been published so far. 
This clearly contrasts to molecular pathological find-
ings in all other subtypes of SM, where KITD816V is 
detectable in more than 90% of the cases  [23] . 
 (4) Synchronous existence of KITD816V and another im-
portant activating point mutation found in myelopro-
liferative neoplasms like polycythemia vera and pri-
mary myelofibrosis, namely JAK2V617F, has been 
shown and is found in SM associated with primary 
myelofibrosis. It is therefore recommended to look for 
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 Take-Home Messages 
 (1) Most cases of mastocytosis can be diagnosed and sub-
typed by the pathologist who should strictly apply de-
fined WHO criteria. 
 (2) Compact tissue mast cell infiltrates are the morpho-
logical key finding to establish or exclude mastocyto-
sis in the majority of cases. 
JAK2V617F in cases of SM-AHNMD with marked in-
filtration of the bone marrow and suspicion but not 
proof of an ‘AHNMD’ of myeloproliferative neoplasm 
type. However, it must also be considered that micro-
dissected mast cells in cases of SM and associated pri-
mary myelofibrosis have been found to carry both ac-
tivating mutations KITD816V and JAK2V617F  [24] . 
 Fig. 21–24. Myeloproliferative neoplasm with eosinophilia 
 (MPNEo). Bone marrow histology reveals dense infiltrates of eo-
sinophilic granulocytes leading to the differential diagnoses of 
chronic eosinophilic leukemia (NOS) or myeloproliferative neo-
plasm with eosinophilia (MPNEo). Presence of large numbers of 
spindle-shaped mast cells with aberrant expression of CD25 is only 
seen in MPNEo. Since compact mast cell infiltrates are missed, di-
agnosis of SM-AHNMD cannot be established. Cytogenetic analy-
sis showed presence of an anomaly in the PDGFR-alpha confirming 
diagnosis of MPNEo. Bone marrow smears also show abundant 
atypical hypogranulated loosely scattered mast cells and an increase 
in eosinophils. Blood smear contains atypical hypogranulated cir-
culating eosinophils with hypersegmented nuclei. Giemsa (fig. 21). 
Anti-CD25 (ABC method) (fig. 22). Wright-Giemsa (fig. 23, 24). 
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 (3) Histological evaluation of a bone marrow trephine bi-
opsy specimen is crucial for diagnosis of systemic 
mastocytosis. 
 (4) In a minority of cases diagnosis of mastocytosis is only 
possible when molecular (KITD816V) and serological 
(elevated tryptase) parameters are also included in the 
diagnostic approach. 
 (5) Mastocytosis includes a great variety of differential di-
agnoses including basophilic, eosinophilic and mono-
cytic leukemias but also overlap-syndromes like my-
elomastocytic leukemia. 
 (6) Differential diagnoses of mastocytoses differ greatly 
depending not only on the subtype of the disease and 
the degree of bone marrow infiltration but also on cy-
tomorphological and immunophenotypical features 
of mast cells involved. 
